生物试剂
>
生化试剂
>
信号通路
> BML-111
加入收藏 取消收藏

BML-111  ≥95%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：1mg in glass bottle
产品描述：基本信息 产品编号： B11383 产品名称： BML-111 CAS: 78606-80-1   储存条件 粉末 -20℃ 四年     分子式： C8H16O5 溶于液体 -80℃ 六个月 分子量 192.21 -20℃ 一个月 化学名：  (5S,6R)-Methyl 5,6,7-trihydroxyheptanoate   生物活性 产品描述 一种脂蛋白 A4 类似物，是一种脂蛋白 A4 (lipoxin A4) 受体激动剂。BML-111 可抑制血管紧张素转化酶 (ACE) 的活性，并增加血管紧张素转化酶 2 (ACE2) 的活性。BML-111 具有抗血管生成，抗肿瘤和抗炎的特性。 靶点 Lipoxin A4 receptor Angiotensin converting enzyme (ACE) 体外研究 In H22 cells, BML-111 inhibits the production of vascular endothelial growth factor and reduces hypoxia-inducible factor-1α level. BML-111 inhibits leukotriene B4-induced cellular migration with an IC50 of 5nM 体内研究 BML-111 (1mg/kg; intraperitoneal injection; for 15 days; male Imprinting Control Region mice) treatment suppresses tumorrelated angiogenesis and tumor growth in vivo. BML-111 also enhances the in situ apoptosis while inhibiting macrophage infiltration in tumor tissue. BML-111 protects LPS-induced acute lung injury and LPS/D-GalN-induced acute liver injury. BML-111 represses the activity of ACE, but increases the activity of ACE2. BML-111 decreases the expression levels of ACE, AngII, and AngII type 1 receptor (AT1R), meanwhile increases the levels of ACE2, angiotensin-(1-7) (Ang-1-7), and Mas Animal Model: Male Imprinting Control Region mice (5-6-week-old,18-22 g) injected with H22 cells Dosage: 1mg/kg Administration: Intraperitoneal injection; injected 5 minutes before and 4 hours after H22 cell inoculation, then every 12 hours for 2 consecutive days, then daily in an additional 3 days and every other day for the last 10 days Result: Suppressed tumor-related angiogenesis and tumor growth in vivo.
保存条件：-20℃

猜你喜欢